Selvita S.A.

Zadzwoń Wskazówki dojazdu Strona internetowa Kontakt: firmę

Selvita S.A. Integrated Drug Discovery | Drug Development | Contract Research The Company’s research sites are in Krakow (HQ), Poznan, Poland, and Zagreb, Croatia.

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

Selvita provides comprehensive solutions supporting Clients and their drug discovery projects, across a broad range of therapeutic areas, specializing in infectious diseases, inflammation, fibrosis, and oncology. The Company offers a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development. On top of that Selvita also offers analytical support of drug development and contract testing studies.

Selvita, established in 2007, operates globally with over 900 highly qualified employees, of which over 40% hold a PhD degree. The international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Ardigen, a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine, is part of Selvita Group portfolio of companies.

Selvita is listed on the Warsaw Stock Exchange (WSE: SLV).

Same gene, same virus, two different hosts: do you get the same protein? It’s less obvious than it sounds, and that’s wh...
16/11/2026

Same gene, same virus, two different hosts: do you get the same protein?

It’s less obvious than it sounds, and that’s what our latest blog article, “One Baculovirus, Two Eukaryotic Hosts: Rethinking Recombinant Protein Production” by Anna Niewiarowska-Sendo, explores. It looks at what happens when a single baculovirus is used to produce the same protein in insect and mammalian cells.

We developed the Multi-Eukaryotic Expression System: one modified baculovirus that works in both insect and mammalian cells. We used it to produce the same target protein in both hosts and compared the results side by side.

The question isn’t only “How much protein did we make?” but “What protein did we actually get?” The answer is in the blog article: https://eu1.hubs.ly/H0zVCRl0

How can we demonstrate that a biosimilar insulin is truly comparable to its reference product?🎙️ Listen to the new episo...
12/11/2026

How can we demonstrate that a biosimilar insulin is truly comparable to its reference product?

🎙️ Listen to the new episode of Science Talks by Selvita, based on our latest scientific article: When Looking Alike Isn't Enough: Building the Functional Evidence for Insulin Biosimilarity.

In the first part of our series, we explore why functional characterization is essential in biosimilar insulin development and how complementary, orthogonal assays help build a robust body of evidence.

▶️ Watch on YouTube: https://eu1.hubs.ly/H0zQR9X0
🎧 Listen on Spotify: https://eu1.hubs.ly/H0zQR9Y0

Read the full article:
https://eu1.hubs.ly/H0zQR9-0

Antibodies are on the agenda at PEGS Europe 2026, and so are we.Elżbieta Plebanek and Irwin Matyjaszczyk are heading to ...
10/11/2026

Antibodies are on the agenda at PEGS Europe 2026, and so are we.

Elżbieta Plebanek and Irwin Matyjaszczyk are heading to Lisbon. Irwin has spent years working hands-on with antibodies, so if developability, candidate selection or your next project steps are on your mind, they’d be glad to chat.

For those who’d like to dig deeper into developability before the event, we have a blog article and a poster on our website:
📝 Early-Stage Developability Assessment: From 800 Monoclonal Antibodies to Data-Driven Lead Selection (https://eu1.hubs.ly/H0zCdFG0)
📊 Early Developability Assessment (EDA) as a Data Driven Precursor for Robust AI/ML Model Training Pipelines (https://eu1.hubs.ly/H0zCdGc0

Herbal remedies can feel harmless, but what happens when they meet a prescription drug?  Hydroquinone, the main active c...
09/11/2026

Herbal remedies can feel harmless, but what happens when they meet a prescription drug?

Hydroquinone, the main active compound in bearberry, is sometimes taken alongside the antibiotic nitrofurantoin to treat urinary tract infections. A new publication co-authored by our colleague, Ana Butorac, asks whether this combination is as safe as it seems.

In T24 human bladder cells, the two compounds together caused stronger cytotoxic and genotoxic effects than either one alone. Although these findings are based on cell-line experiments and further research is needed to determine whether the same effects occur in humans, the results suggest that this combination may warrant caution.

So, as safe as it seems? Not entirely. Natural doesn’t always mean risk-free, especially when it’s taken together with a drug.

The full study is now available on our website: https://eu1.hubs.ly/H0zDsp90

The best-performing formulation is not always the best formulation.A prototype may perform well in the lab. But what hap...
06/11/2026

The best-performing formulation is not always the best formulation.

A prototype may perform well in the lab. But what happens when API properties, excipient characteristics or process conditions change?

QbD shifts the focus from “Which formulation works?” to “Which formulation remains robust when variability is introduced?”

That shift can make a significant difference later in development.

Explore the full perspective in our latest blog, by Wiktoria Zych: https://eu1.hubs.ly/H0zzKzj0

We are pleased to share our recent interview with The Europe Times, a Japanese business media platform covering European...
05/11/2026

We are pleased to share our recent interview with The Europe Times, a Japanese business media platform covering European companies, innovation, and sustainability.

In the interview, we discussed:
🔬 How our integrated drug discovery and development services support pharmaceutical and biotechnology companies worldwide.
🤖 How we are applying generative AI to drug discovery and CAR-T cell therapy development.
🎓 How we foster scientific talent, interdisciplinary collaboration, and continuous learning across our organisation.

The article is available in Japanese and English, offering insights into our approach to scientific innovation, people development, and long-term growth.

🔗 Read the full interview: https://eu1.hubs.ly/H0zDmL70

Are e-ci******es really a safer alternative to conventional ci******es?In our new blog, Vesna Eraković Haber examines th...
04/11/2026

Are e-ci******es really a safer alternative to conventional ci******es?

In our new blog, Vesna Eraković Haber examines the evidence linking e-cigarette-related lung injury to chronic respiratory disease.

Clinical and epidemiological data establish the presence of harm, yet the processes through which injury is initiated, sustained and potentially converted into persistent disease remain incompletely understood. Does e-cigarette-related lung injury remain confined to the acute phase, or can it progress to persistent inflammation, tissue remodelling and chronic respiratory disease? The article discusses these questions and shares observations from our own work.

Read the full article: https://eu1.hubs.ly/H0zCVst0

What does reliable nitrosamine analysis take?Selecting the right analytical technique is only one part of the equation. ...
03/11/2026

What does reliable nitrosamine analysis take?

Selecting the right analytical technique is only one part of the equation. Sample preparation, matrix effects, sensitivity, and method limitations can all influence the reliability of results.

In our upcoming webinar, our experts will explore the key challenges in nitrosamine analysis and practical approaches to addressing them, from understanding different nitrosamine types to implementing robust methods in routine quality control.

Discover the topics we’ll cover, including analytical technique selection, quantification limits, method development, and routine QC implementation.

📅 November 25, 2026
🕑 1:00 PM CET

Register: https://eu1.hubs.ly/H0zz2Y40

🧩 Induced-proximity drugs work by bringing the right proteins together, and no single assay captures every step of that ...
02/11/2026

🧩 Induced-proximity drugs work by bringing the right proteins together, and no single assay captures every step of that process.

Our poster “Integrated Cell-Free and Cellular Assays for Induced Proximity Drug Discovery: From Protein Interactions to Functional Degradation” was presented by Steve Price at ELRIG Drug Discovery 2026. It brings together cell-free and cellular assays, including SPR-based cooperativity analysis and live-cell NanoBiT proximity assays, to look at each molecule from several angles.

The full poster is waiting for you on our website: https://eu1.hubs.ly/H0zztDm0

Something spooky is happening in the lab 👻🧪 Our scientists bringing a little Halloween spirit 🎃
30/10/2026

Something spooky is happening in the lab 👻🧪

Our scientists bringing a little Halloween spirit 🎃

Adres

Bobrzyńskiego 14
Kraków
30-348

Telefon

+48122974700

Strona internetowa

Powiadomienia

Bądź na bieżąco: wyślemy Ci e-mail, gdy Selvita S.A. opublikuje nowości i promocje. Twój adres e-mail nie zostanie wykorzystany do żadnego innego celu, a subskrypcję możesz anulować w dowolnym momencie.

Kontakt: Firmę

Wyślij wiadomość do Selvita S.A.:

Skróty

Udostępnij

Firmy Inżynieryjne w pobliżu